To the Editor:
Although the results of the multicenter, randomized, controlled Neuroendocrine Tumors Therapy (NETTER-1) trial reported by Strosberg et al. (Jan. 12 issue) validate the experience gained over the past decade by many institutions, we think that they overstate the toxic effects of lutetium-177 (177Lu)–Dotatate and potentially underestimate its efficacy relative to other potential therapies for these tumors. [...]

Additional Metadata
Persistent URL,
Journal New England Journal of Medicine
Strosberg, J.R, & Krenning, E.P. (2017). 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 376(14), 1391–1392. doi:10.1056/NEJMc1701616